Table 2.

Characteristics of patients who were alive 2-years after transplantation.

Characteristic	Number (percent)
Number	950
Age at transplant, years
≤10	458 (48%)
11 – 17	276 (29%)
18 – 29	142 (15%)
30 – 39	47 (5%)
40 – 49	21 (2%)
≥ 50	6 (1%)
Sex, male/female	531(56%)/419(44%)
Disease type, Hemoglobin SS/SP-thalassemia	917(97%)/33(3%)
Performance score
≤ 80	187 (20%)
90 – 100	711 (75%)
Not reported	52 (5%)
Donor type
HLA-matched sibling	627 (66%)
Haploidentical relative	124 (13%)
HLA-matched unrelated	95 (10%)
HLA-mismatched unrelated	104 (11%)
Graft type
Bone marrow	669 (70%)
Peripheral blood	167 (18%)
Umbilical cord blood	114 (12%)
Conditioning regimen intensity
Myeloablative	496 (52%)
Reduced-intensity	237 (25%)
Non-myeloablative	173 (18%)
Not reported	44 (5%)
In vivo T-cell depletion
None	67 (7%)
Yes	864 (91%)
GVHD prophylaxis
Ex vivo T-cell depletion	15 (2%)
CD 34 selection	34 (4%)
Post-transplant cyclophosphamide/CNI/other	92 (10%)
CNI/mycophenolate or methotrexate	643 (68%)
CNI/prednisone	63 (7%)
Other	103 (11%)
History of grade II-IV acute GVHD
None	777 (82%)
Yes	146 (15%)
Not reported	27 (3%)
History of chronic GVHD
None	727 (77%)
Yes	217 (23%)
Not reported	6 (1%)
Transplant period
2000 – 2005	101 (11%)
2006 – 2010	182 (19%)
2011 – 2015	443 (47%)
2016 – 2017	224 (24%)
Follow up, median (range), months	62 (24 – 244)

Abbreviation:

CNI = calcineurin inhibitor

GVHD = graft versus host disease

Conditioning regimen intensity

Myeloablative: busulfan was administered orally at a concentration greater than 8 mg/kg or intravenously at a concentration greater than 6 mg/kg, or melphalan was administered at concentrations greater than 150 mg/m²

Reduced intensity: lower doses of busulfan or melphalan

Non-myeloablative: Total body irradiation regimens (dose 200–400 cGy) alone or with cyclophosphamide and/or fludarabine